Related Experiment Video
Updated: Aug 5, 2026
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
[The Clinical Significance of ARHGAP10 Alterations in Acute Myeloid Leukemia]
Ting-Ting DU1,2, Zi-Jun Xu1,2, Xiang-Mei Wen1,2
1Central Laboratory, The Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002， Jiangsu Province， China.
Objective:
To investigate the expression and methylation alterations of ARHGAP10 in AML and to further explore its clinical significance.
Methods:
ARHGAP10 expression was measured by RT-qPCR in 18 controls and 68 AML patients. ARHGAP10 methylation was assessed using targeted sulfite sequencing in 25 controls and 102 AML patients. The clinical significance of ARHGAP10 expression and methylation changes in AML was further analyzed.
Results:
Analysis of publicly available datasets identified increased expression of ARHGAP10 in AML patients, which was further validated in our hospital cohort. Among the FAB subtypes, ARHGAP10 expression was significantly higher in the M2 and M5 subgroups compared to the control group. ROC curve analysis indicated that ARHGAP10 expression could be a potential diagnostic biomarker for AML. Kaplan-Meier analysis showed that high ARHGAP10expression and ARHGAP10 hypomethylation were associated with shorter overall survival. Furthermore, ARHGAP10 hypomethylation was observed in AML patients, and further analysis revealed a negative correlation between ARHGAP10 methylation level and expression level.
Conclusion:
ARHGAP10 exhibits high expression and hypomethylation changes in AML, and these alterations may serve as potential indicators of poor prognosis in AML patients.
